You are here:Home-Victor Kouassi
Avatar

About Victor Kouassi

This author has not yet filled in any details.
So far Victor Kouassi has created 43 blog entries.


Knowledge sharing for antimicrobial research: AntibioticDB and SPARK and why researchers should use them
– by Jack Stone and Maria Laura Ciusa

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The number of drug-resistant bacterial infections is rising across the world and new treatments are urgently required1. One of the barriers to discovering new antibiotics is a lack of information sharing.


Knowledge sharing for antimicrobial research: AntibioticDB and SPARK and why researchers should use them
– by Jack Stone and Maria Laura Ciusa
2020-08-05T12:56:07+00:00

Longitude Prize Sprint Workshops

The Longitude Prize has launched a programme called Sprint which consists of expert support and technical workshops in the form of webinars that are available to all. The first webinar will take place on 7th August 2020 at 15:00 BST with the title of 'Navigating MedTech Regulation Pathways in Developed and Emerging Markets'. To find more information and to register click here.

Longitude Prize Sprint Workshops2020-07-20T16:16:56+00:00


Getting the most out of antimicrobial surveillance
– by Mariana Castanheira

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Surveillance has been promoted as an important tool to monitor the prevalence of antimicrobial resistance. Beyond this purpose, surveillance is conducted to identify the increase in prevalence of certain pathogens,


Getting the most out of antimicrobial surveillance
– by Mariana Castanheira
2020-05-28T06:47:56+00:00

CARB-X – How to Prepare for an FDA Pre-IND Meeting: Planning for Success

On 28th May 2020 at 17:00 CEST - 18:00 CEST, CARB-X will host a webinar on how to prepare for an FDA pre-IND meeting. Carmella Moody and Michael Bevilacqua will present on how best to prepare for these meetings to ensure maximum results. To find more information and to register click here.

CARB-X – How to Prepare for an FDA Pre-IND Meeting: Planning for Success2020-05-19T11:17:07+00:00

Webinars from the Global AMR R&D Hub

The Global AMR R&D Hub have announced their first set of webinars. These sessions will be held at two different times to suit various time zones on the 27th May 2020 at 2:00 - 3:00 pm GMT and the 28th May at 07:00 - 08:00 am GMT. The webinars will focus on providing a better understanding of their Dynamic Dashboard. For information on the speakers and to register, please visit the Global AMR R&D Hub website.

Webinars from the Global AMR R&D Hub2020-05-19T12:22:05+00:00


COVID-19 and antimicrobial resistance: Are there any unknowns that will become known?
– by Stephan Harbarth

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” COVID-19 represents an unprecedented public health crisis that will bring many novel insights. This worldwide disturbance will probably affect the epidemiology of antimicrobial resistance (AMR) in many different ways that


COVID-19 and antimicrobial resistance: Are there any unknowns that will become known?
– by Stephan Harbarth
2020-05-13T14:55:19+00:00


COVID-19 and its impact on antimicrobial stewardship
– by Andrew Seaton

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial stewardship (AMS) is a system-wide approach to guiding, promoting and overseeing the safe and judicious use of antimicrobials. An AMS programme aims to safeguard antimicrobials, especially antibiotics, for future


COVID-19 and its impact on antimicrobial stewardship
– by Andrew Seaton
2020-05-07T12:07:20+00:00

GARDP: Bringing new treatments for drug-resistant infections to all who need them

Speakers:  Seamus O' Brien, R&D Director, GARDP François Franceschi, Asset Evaluation and Development Project Leader, GARDP Sally Ellis, Neonatal Sepsis Project Leader, GARDP Moderator: Laura Piddock, Director of Scientific Affairs, GARDP This webinar provided an overview and update on GARDP's efforts to bring new antibiotic treatments for drug-resistant infections to all who need them. The following topics were presented: Antibiotic resistance and the GARDP response Tackling the growing threat of hospital infections Developing new treatments for neonatal sepsis The

GARDP: Bringing new treatments for drug-resistant infections to all who need them2020-07-16T13:57:37+00:00

Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations

Speaker: Vincent H. Tam, Professor, University of Houston College of Pharmacy (USA) Moderator: Shampa Das, Senior Lecturer, Centre of Excellence in Infectious Diseases Research, University of Liverpool (UK)  In this webinar, Vincent H. Tam presented his work on studying PK/PD in fixed dose beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations. Topics discussed included: Understanding the inherent challenges associated with PK/PD of BL/BLI combinations Demonstrating new approaches to gain useful insights from preclinical PK/PD models The presentation was followed by a Q&A session.

Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations2020-06-15T11:05:34+00:00


The critical need for alternative approaches to address antibiotic treatment failure
– by Bob Hancock

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The O’Neill report1 suggested that up to 10 million people will die from antibiotic resistant infections by 2050. This figure has been adopted by health authorities, researchers and the general


The critical need for alternative approaches to address antibiotic treatment failure
– by Bob Hancock
2020-05-07T14:02:41+00:00


COVID-19: Pourquoi il est plus important que jamais de s’attaquer à la crise silencieuse des infections résistantes aux médicaments
– par Manica Balasegaram

Le spectre d’une maladie infectieuse prenant les proportions d’une pandémie et faisant des dizaines de milliers de victimes dans le monde n’est plus un scénario cauchemardesque théorique. La «maladie X» de l’Organisation mondiale de la Santé est là et, malgré les efforts constants déployés par l’OMS et d’autres pour maintenir cette menace au centre des préoccupations politiques, le monde a en grande partie été pris au dépourvu. S’il y a d’ores et déjà des leçons à tirer de la


COVID-19: Pourquoi il est plus important que jamais de s’attaquer à la crise silencieuse des infections résistantes aux médicaments
– par Manica Balasegaram
2020-04-16T11:27:28+00:00

Probability of target attainment analyses for dose selection in antimicrobial drug development

Speaker: Shampa Das, Senior Lecturer, Centre of Excellence in Infectious Diseases Research, University of Liverpool (UK)  Moderator: Vincent H. Tam, Professor, University of Houston (US)  In this webinar, Shampa Das gave an overview of her work in studying the PK/PD and probability of target attainment for dose selection. Topics discussed included: An overview of what is meant by the probability of target attainment (PTA) How it is calculated and what data is used for this How PTA is used

Probability of target attainment analyses for dose selection in antimicrobial drug development2020-05-13T12:46:15+00:00


COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever
– by Manica Balasegaram

Artikel auf Deutsch lesen Lire en français PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The spectre of an infectious disease pandemic killing tens of thousands of people across the globe is no longer a


COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever
– by Manica Balasegaram
2020-05-07T14:04:19+00:00

PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

Speaker: Alexander J. Lepak, Assistant Professor, University of Wisconsin School of Medicine and Public Health (US) Moderator: Peter Warn, Magic Bullet Consulting (UK) In this webinar, Alexander J. Lepak reviewed critical study elements that lead to robust preclinical PK/PD results in the murine model. Topics discussed included: Understanding and embracing the inherent variability in many components of the murine model Demonstrating how to generate and interpret preclinical murine model PK/PD results The presentation was followed by a Q&A session. *

PK/PD murine infection models: Focus on study elements, variability, and interpretation of results2020-03-02T15:21:13+00:00


Bringing antimicrobial research and development to Africa – the time is now
– by Greg Basarab and Kelly Chibale

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial resistance (AMR) has been an ongoing threat to public health in South Africa as well as other countries in Africa. Disturbingly, the burden in the continent from infectious diseases


Bringing antimicrobial research and development to Africa – the time is now
– by Greg Basarab and Kelly Chibale
2020-05-07T16:40:50+00:00


Are new antibiotic combinations the solution to the AMR crisis?
– by Anthony Coates

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The traditional model for the development and marketing of new chemical entity (NCE) antibiotics has collapsed. The companies which develop NCEs for resistant bacteria struggle to survive in the market. NCE


Are new antibiotic combinations the solution to the AMR crisis?
– by Anthony Coates
2020-05-07T16:35:02+00:00

Jeffrey Ambroso

Jeffrey L. Ambroso is a board-certified toxicologist with 21 years of experience in nonclinical safety evaluation of drugs and biotechnology products, in both public and private sectors. At RTI International, Jeffrey works closely with both the TB Alliance and CARB-X to develop novel therapies to treat bacterial pathogens. He has served as the preclinical safety representative on multiple project teams developing drugs for a variety of indications.

Jeffrey Ambroso2020-05-28T14:04:29+00:00

Antoine Andremont

Antoine Andremont is currently Emeritus Professor at the Paris Diderot University Medical School, France, a scientific advisor at the French Ministry of Higher Education, Research and Innovation, and serves as an expert witness for the French National Highest Judiciary Court (Cour de Cassation). He is also the co-founder and a senior scientific advisor at biotechnology company Da Volterra - which he created in 2000 to research and understand the impact of antibiotics on the intestinal flora microbiota, the development and

Antoine Andremont2020-02-04T10:06:36+00:00

John N. van den Anker

John van den Anker is a renowned paediatric consultant based at the Children’s National Medical Center Washington, DC, whose research has resulted in a much more evidence-based use of antibacterial agents such as aminoglycosides, cephalosporins, penicillins, meropenem, and vancomycin in children. John holds many titles including, the Evan and Cindy Jones Endowed Professor of Paediatric Clinical Pharmacology at Children’s National Medical Center; the Eckenstein-Geigy Distinguished Professor in Paediatric Pharmacology and Pharmacometrics at the University of Basel Children’s Hospital in Switzerland,

John N. van den Anker2020-02-04T10:07:09+00:00

Carl Balibar

Carl Balibar is a Principal Scientist in the department of Infectious Disease and Vaccines at Merck & Co. which he joined in 2012. He is an expert in antibiotic mechanism of action and antibacterial drug discovery. He is specifically responsible for efforts ranging from early discovery and target validation through clinical development utilizing various modalities in support of anti-infective drug discovery. Carl has written more than 30 papers and book chapters and participated in the discovery and development of the

Carl Balibar2020-05-28T13:57:30+00:00

Peter Beyer

Peter Beyer is a trained lawyer and Senior Advisor at the World Health Organization (WHO) where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments. Peter was involved in establishing the Global Antibiotic R&D Partnership (GARDP) as a WHO and DNDi joint initiative as well as the trilateral collaboration among the World Intellectual Property Organization (WIPO), the World Trade

Peter Beyer2020-05-28T13:56:06+00:00

James Collins

James (Jim) Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT), as well as a member of the Harvard-MIT Health Sciences & Technology Faculty. He is a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and an Institute Member of the Broad Institute of MIT and Harvard. Being one of the founders of the field of synthetic biology, his research

James Collins2020-05-28T13:55:18+00:00

Lloyd Czaplewski

Lloyd Czaplewski is Chief Scientific Officer for Persica Pharmaceuticals Limited and a Director of Chemical Biology Ventures where he provides life and chemical sciences consultancy services. Previously, Lloyd has served as an R&D executive for Biota, Prolysis, and British Biotech Pharmaceuticals. In his scientific career so far, he has led the creation and clinical evaluation of an engineered cytokine, discovery of the potential for minimal lentiviral vectors in antigen presentation, and demonstrating ability to create and lead structure-informed screening. He

Lloyd Czaplewski2020-05-28T13:54:16+00:00

David Denning

David Denning is an infectious diseases clinician with expertise in fungal diseases. He has been a Professor of Infectious Diseases and Global Health at the University of Manchester since 2005. From 2009 to 2020, David led the National Aspergillosis Centre, Manchester, a referral centre in the UK for all patients with chronic pulmonary aspergillosis. His current academic interests are chronic and allergic pulmonary fungal disease, the global burden of fungal infection, resistance in Aspergillus and getting new antifungals developed. He

David Denning2020-06-04T07:09:07+00:00

Harpal Dhillon

Harpal Dhillon is a pharmacist, founder of AntiBx and a Global Medical Value consultant. Harpal has amassed over 15 years of experience working across healthcare, public health, academia and the pharmaceutical industry in a variety of roles within infectious diseases. He has specialized in developing innovative strategies and initiatives to optimize antibiotic prescribing. This has included the launch of TARGET antibiotics in the UK and the execution of an EU-wide compassionate use programme for an antibiotic. His experience led to

Harpal Dhillon2020-06-22T14:46:30+00:00

Cecilia Ferreyra

Cecilia joined the Foundation for Innovative New Diagnostics (FIND) as AMR Medical Officer in 2018. Here, she supports projects addressing gaps in the availability and use of diagnostic tests for antimicrobial resistance in order to better guide the appropriate use of treatments. Prior to joining FIND, Cecilia worked at Médecins Sans Frontières (MSF) for 14 years in several countries such as China, Somalia, South Sudan and Uganda. In this role, she implemented HIV and tuberculosis (TB) activities in conflict affected

Cecilia Ferreyra2020-05-28T13:50:21+00:00

Lena Friberg

Lena Friberg is Professor of Pharmacometrics at the Faculty of Pharmacy at Uppsala University, Sweden, a position she has held since 2014. Lena obtained her PhD degree in Pharmacokinetics and Drug Therapy in 2003 and spent nearly two years as a postdoctoral fellow at the University of Queensland in Australia. She has published over 125 original articles and nearly 15 reviews and book chapters in the area and has an H-index over 40. Her research is focused on advancing pharmacometric

Lena Friberg2020-06-04T08:29:48+00:00

Paul Hergenrother

Paul J. Hergenrother is the Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry at The University of Illinois at Urbana-Champaign. He established his own laboratory in 2001 which seeks to understand compound accumulation in Gram-negative bacteria to then use this information to create novel antibiotics. Paul is the co-founder and Chief Scientific Officer of Vanquish Oncology, and an anticancer compound discovered by his lab is now being used in multiple clinical trials. Paul has received numerous awards including the

Paul Hergenrother2020-05-28T13:45:40+00:00

Edward W Hook III

Edward W. Hook III is an Emeritus Professor of Medicine at the University of Alabama at Birmingham (USA) with expertise in infectious diseases, microbiology and epidemiology. In his role as a clinical investigator with a focus on sexually transmitted infections, Edward has led and participated in clinical trials of new antimicrobials, vaccines, and diagnostic tests as well as conducting epidemiologic research on a variety of topics. He has consulted with the National Institutes of Health (NIH), the Centers for Disease

Edward W Hook III2020-05-28T13:45:04+00:00

Diarmaid Hughes

Diarmaid Hughes is Professor of Medical Molecular Bacteriology at Uppsala University, Sweden. He has been working actively within the Innovative Medicines Initiative (IMI), New Drugs for Bad Bugs (ND4BB), ENABLE Project since its beginning in February 2014. ENABLE is a public-private partnership involving collaboration between more than 40 partners including several European Federation of Pharmaceutical Industries and Associations (EFPIA) companies, multiple small and medium-sized enterprises, research institutes, academic hospitals and universities spread throughout Europe. ENABLE’s remit is to develop promising

Diarmaid Hughes2020-05-28T14:30:52+00:00

Anders Karlén

Anders Karlén is a professor of Computer-Aided Drug Design at Uppsala University and focuses on hit identification and lead development in antibacterial drug discovery. His research group studies targets of importance in infectious diseases with a focus on tuberculosis and Gram-negative infections. At Uppsala University, he is the overall medicinal chemistry project leader for drug discovery efforts directed at several different anti-bacterial targets. Since February 2014, Anders has led the Managing Entity as well as been co-coordinator of the project

Anders Karlén2020-05-28T13:43:42+00:00

Cassandra Kelly-Cirino

Cassandra Kelly-Cirino is Director of Emerging Threats at the Foundation for Innovative New Diagnostics (FIND). She joined this organization in 2017 with over 20 years of experience working in Canadian and US public health and private sector settings. Most recently, Cassandra was responsible for multiple initiatives to bring simple collection and stabilization solutions to the global public health and outbreak response fields at DNA Genotek. She has supported the development of public health policy for infectious diseases with a focus

Cassandra Kelly-Cirino2020-05-28T13:42:50+00:00

Kevin Krause

Kevin Krause is Vice President of Clinical Sciences and Development at AN2 Therapeutics, a company he joined in November 2019. Here, he focuses on the development of treatments for infectious diseases with a high unmet need. Before joining AN2 Therapeutics, Kevin was part of the senior leadership team at Achaogen. During his time there, Kevin led plazomicin out-licensing efforts for key regions. He also played an instrumental role in the phase 3 development programme, regulatory defense and launch of this

Kevin Krause2020-05-28T13:39:58+00:00

Ramanan Laxminarayan

Ramanan Laxminarayan is founder and director of the Center for Disease Dynamics, Economics & Policy (CDDEP) and a senior research scholar at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Strathclyde in Scotland as well as the University of Kwazulu Natal in South Africa. He also chairs the boards of GARDP and HealthCubed. Since 1995, Ramanan has worked to improve the understanding of antibiotic resistance as a problem

Ramanan Laxminarayan2020-05-28T13:38:35+00:00

Alexander Lepak

Alexander Lepak is an Assistant Professor at the University of Wisconsin in the Department of Medicine, Division of Infectious Diseases. He is an active physician, educator and researcher. Alexander directs antimicrobial stewardship quality improvement initiatives and research projects. His main research pursuits are in performing and translating antimicrobial pharmacodynamic (PD) studies (both in vivo animal models and patient-level data) to optimize therapy against numerous pathogens. This research has specifically included medically important fungal and bacterial pathogens, including those that are

Alexander Lepak2020-05-28T14:35:23+00:00

Troy Lister

Troy Lister is Vice President of Research and Development at Spero Therapeutics in Cambridge, Massachusetts. Before joining Spero Therapeutics in 2014, Troy was previously team leader of infection chemistry at AstraZeneca and Investigator III in Global Discovery Chemistry at the Novartis Institute for BioMedical Research (NIBR). He has led numerous discovery programmes searching for novel agents to target bacterial and viral pathogens including both Gram-negative and Gram-positive multidrug-resistant bacteria as well as other pathogens such as respiratory syncytial virus and

Troy Lister2020-05-28T13:35:29+00:00

Marc Mendelson

Marc Mendelson is a Professor and Head of the Division of Infectious Diseases and HIV Medicine at Groote Schuur Hospital, University of Cape Town. He is Chair of the South African Ministerial Advisory Committee on AMR and co-founder of the South African Antibiotic Stewardship Programme. His interests lie within national and international policy development on AMR as well as building antibiotic stewardship models in low-resource settings. Marc works with the World Health Organization (WHO) on several of its AMR technical

Marc Mendelson2020-06-04T06:57:45+00:00

Michael Mourez

Michael Mourez is Head of the Bacteriomics platform at Evotec in Lyon, France. He previously worked at Sanofi on their discovery platform in the therapeutic area of infectious diseases and then at Evotec once Sanofi transferred this portfolio. Michael is now located in Lyon, where he oversees technology platforms addressing severe bacterial infections, especially drug resistance. Michael received a Canada Research Chair Award for his work on bacterial animal diseases as well as numerous grants and awards. Michael trained in

Michael Mourez2020-05-28T13:31:35+00:00

Kevin Outterson

Kevin Outterson is Executive Director at CARB-X and Professor of Health and Disability Law at Boston University where he co-directs the Health Law Program. Kevin also serves as a principal investigator at CARB-X, an international public-private partnership to accelerate global antibacterial innovation. Key partners of CARB-X include the National Institute of Allergy and Infectious Diseases (NIAID) in the US Government as well as the Wellcome Trust and the Bill & Melinda Gates Foundation. He has led CARB-X since August 2016.

Kevin Outterson2020-05-28T13:30:26+00:00

John Rex

John Rex is Chief Medical Officer and Director of F2G, LTD, a UK-based antifungal drug discovery and development company. He is a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. Throughout his career, he has moved antifungal and antibacterial agents from preclinical development through all development phases. He has held academic positions in the USA at the National Institute of Allergy and Infectious Diseases (NIAID) and the University of Texas

John Rex2020-05-28T13:29:39+00:00

Ursula Theuretzbacher

Ursula Theuretzbacher founded the Center of Anti-Infective Agents, Vienna, Austria in 1988. She is an expert within antibacterial drug Research and Development (R&D) strategies and policies based on clinical and public health needs. Her broad therapeutic areas of expertise include early integration of pharmacokinetic/pharmacodynamic (PK/PD) concepts, optimization of dosing and usage approaches, public funding strategies for antibacterial R&D and initiatives to recover the global pipelines. Previously, she was work package leader or partner in several EU funded international collaborative projects

Ursula Theuretzbacher2020-06-23T12:51:36+00:00

Françoise Van Bambeke

Françoise Van Bambeke is Research Director of the Belgian Fonds National de la Recherche Scientifique (FNRS) and leads a research group at the Louvain Drug Research Institute at the Université catholique de Louvain in Brussels, Beligium, which focuses on antibiotic pharmacology. Her main research interests are the study of pharmacokinetic and pharmacodynamic parameters that affect antibiotic activity against persistent forms of infections (intracellular infection, biofilm) and the search for innovative strategies against such infections. She also investigates the resistance mediated

Françoise Van Bambeke2020-05-28T13:26:56+00:00

William Weiss

William (Bill) Weiss is Director of PreClinical Services in the University of North Texas (UNT) System College of Pharmacy at the UNT Health Science Center in Fort Worth. There he uses his 40 years of experience and expertise in infectious disease research to direct the evaluations of antibacterial agents, including established models of both acute and chronic bacterial infections in several different animal species as well as pharmacokinetic studies and HPLC/LCMS analysis in collaboration with large pharmaceutical companies, the biotech

William Weiss2020-05-28T13:23:49+00:00